Zacks Research Has Negative Outlook for TEVA Q1 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a report issued on Monday, April 28th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.47 per share for the quarter, down from their prior estimate of $0.48. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Several other equities research analysts have also weighed in on the stock. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Up 0.8 %

Shares of NYSE:TEVA opened at $15.64 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $22.80. The company’s fifty day moving average is $15.11 and its two-hundred day moving average is $17.51. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a market capitalization of $17.73 billion, a price-to-earnings ratio of -10.78, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Diversify Advisory Services LLC increased its stake in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after buying an additional 496 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after acquiring an additional 699 shares in the last quarter. Bfsg LLC increased its stake in shares of Teva Pharmaceutical Industries by 7.8% during the first quarter. Bfsg LLC now owns 10,960 shares of the company’s stock valued at $168,000 after acquiring an additional 790 shares during the period. Townsquare Capital LLC raised its holdings in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock worth $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC lifted its position in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock worth $302,000 after purchasing an additional 860 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.